Advancements in the treatment of agitation in Alzheimer’s disease

Bibliography

• Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimer’s Demen 2013;9(1):63-75
   PubMed Web of Science ®Google Scholar
• McKeith I, Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol 2005;4(11):735-42
   PubMed Web of Science ®Google Scholar
• Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: The cache county study. Int J Geriatr Psychiatry 2008;23(2):170-7
   PubMed Web of Science ®Google Scholar
• Gonfrier S, Andrieu S, Renaud D, et al. Course of neuropsychiatric symptoms during a 4-year follow up in the REAL-FR cohort. J Nutr Health Aging 2012;16(2):134-7
   PubMed Web of Science ®Google Scholar
• Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: Recommendations from a multidisciplinary expert panel. J Am Geriatr So 2014;62(4):762-9
   PubMed Web of Science ®Google Scholar
• Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in alzheimer disease: The CitAD randomized clinical trial. JAMA 2014;311(7):682-91
   PubMed Web of Science ®Google Scholar
• Okura T, Langa KM. Caregiver burden and neuropsychiatric symptoms in older adults with cognitive impairment: The aging, demographics, and memory study (ADAMS). Alzheimer Dis Assoc Disord 2011;25(2):116
   PubMed Web of Science ®Google Scholar
• Okura T, Plassman BL, Steffens DC, et al. Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the united states: The aging, demographics, and memory study. J Am Geriatr Soc 2010;58(2):330-7
   PubMed Web of Science ®Google Scholar
• Okura T, Plassman BL, Steffens DC, et al. Neuropsychiatric symptoms and the risk of institutionalization and death: The aging, demographics, and memory study. J Am Geriatr Soc 2011;59(3):473-81
   PubMed Web of Science ®Google Scholar
• Cummings J, Mintzer J, Brodaty H, et al. Agitation in cognitive disorders: International psychogeriatric association provisional consensus clinical and research definition. Int Psychogeriatr 2015;27(1):7-17
   PubMed Web of Science ®Google Scholar
• Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA 2012;308(19):2020-9
   PubMed Web of Science ®Google Scholar
• Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis. JAMA 2011;306(12):1359-69
   PubMed Web of Science ®Google Scholar
• Small GW. Treating dementia and agitation. JAMA 2014;311(7):677-8
   PubMed Web of Science ®Google Scholar
• Drye LT, Ismail Z, Porsteinsson AP, et al. Citalopram for agitation in Alzheimer’s disease: Design and methods. Alzheimer’s Demen 2012;8(2):121-30
   PubMed Web of Science ®Google Scholar
• Ballard C, Howard R. Neuroleptic drugs in dementia: Benefits and harm. Nat Rev Neurosci 2006;7(6):492-500
   PubMed Web of Science ®Google Scholar
• Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. Am J Geriat Psychiat 2006;14(3):191-210
   PubMed Web of Science ®Google Scholar
• Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Risk 2012;169(1):71-9
   Google Scholar
• Langballe EM, Engdahl B, Nordeng H, et al. Short-and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: A population-based study. Am J Geriatr Psychiat 2014;22(4):321-31
   PubMed Web of Science ®Google Scholar
• Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990;38(5):553-63
   PubMed Web of Science ®Google Scholar
• De Deyn P, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53(5):946-55
   PubMed Web of Science ®Google Scholar
• Lonergan E, Luxenberg J, Colford JM, Birks J. Haloperidol for agitation in dementia. Cochrane Library 2002(5):CD002852
   Google Scholar
• Ballard CG, Gauthier S, Cummings JL, et al. Management of agitation and aggression associated with alzheimer disease. Nat Rev Neurol 2009;5(5):245-55
   PubMed Web of Science ®Google Scholar
• Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: A randomized, placebo-controlled clinical trial. Neurology 2000;55(9):1271-8
   PubMed Web of Science ®Google Scholar
• Geda YE, Schneider LS, Gitlin LN, et al. Neuropsychiatric symptoms in alzheimer’s disease: Past progress and anticipation of the future. Alzheimer’s Demen 2013;9(5):602-8
   PubMed Web of Science ®Google Scholar
• Pope LE, Khalil M, Berg JE, et al. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J Clin Pharmacol 2004;44(10):1132-42
   PubMed Web of Science ®Google Scholar
• Cummings J, Lyketsos C, Tariot P, et al. Dextromethorphan/quinidine (AVP-923) efficacy and safety for treatment of agitation in alzheimer’s disease (AD): Results from a phase 2 study (NCT01584440). Wiley-Blackwell; Hoboken, NJ, USA: 2014. p. S100-1
   Google Scholar
• Townsend M, Cleary JP, Mehta T, et al. Orally available compound prevents deficits in memory caused by the alzheimer amyloid‐β oligomers. Ann Neurol 2006;60(6):668-76
   PubMed Web of Science ®Google Scholar
• Tariot P, Lyketsos C, Crans G, et al. The effects of ELND005 (scyllo-inositol) on emergence of neuropsychiatric symptoms (NPS) in mild/moderate alzheimer’s disease: Results from a 78-week phase 2 study (P04. 215). Neurology 2012;78(Meeting Abstracts 1):P04-215
   Google Scholar
• Salloway S, Sperling R, Keren R, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate alzheimer disease. Neurology 2011;77(13):1253-62
   PubMed Web of Science ®Google Scholar
• Blanchard BJ, Chen A, Rozeboom LM, et al. Efficient reversal of alzheimer’s disease fibril formation and elimination of neurotoxicity by a small molecule. Proc Natl Acad Sci USA 2004;101(40):14326-32
   Google Scholar
• Maeda K, Sugino H, Akazawa H, et al.Brexpiprazole I. In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014;350(3):589-604
   PubMed Web of Science ®Google Scholar
• Haase N, Herse F, Spallek B, et al. Vasoactivity of the alzheimer ss-amyloid peptides is mediated by an activation of the a1-adrenoreceptor. Hypertension 2013;62(3_MeetingAbstracts):A459
   Google Scholar
• Katsouri L, Vizcaychipi MP, McArthur S, et al. Prazosin, an α 1-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of alzheimer’s disease. Neurobiol Aging 2013;34(4):1105-15
   PubMed Web of Science ®Google Scholar
• Peskind ER, Bonner LT, Li G, et al. Adrenergic antagonists for disruptive agitation in nursing home residents with alzheimer’s disease. Neurobiol aging: The 8th international conference on alzheimer’s disease and related disorders, 20 – 25 July 2002, Stockholm, Sweden
   Google Scholar
• Wang LY, Shofer JB, Rohde K, et al. Prazosin for the treatment of behavioral symptoms in patients with alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry 2009;17(9):744-51
   PubMed Web of Science ®Google Scholar
• Ramirez BG, Blazquez C, Gomez del Pulgar T, et al. Prevention of alzheimer’s disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J Neurosci 2005;25(8):1904-13
   PubMed Web of Science ®Google Scholar
• Woodward MR, Harper DG, Stolyar A, et al. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. Am J Geriatr Psychiat 2014;22(4):415-19
   PubMed Web of Science ®Google Scholar
• Drye LT, Spragg D, Devanand DP, et al. Changes in QTc interval in the citalopram for agitation in Alzheimer’s disease (CitAD) randomized trial. PLoS One 2014;9(6):e98426
   PubMedGoogle Scholar
• Livingston G, Johnston K, Katona C, et al. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005;162(11):1996-2021
   PubMed Web of Science ®Google Scholar
• Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: A randomised, placebo-controlled phase 3 trial. Lancet 2014;383(9916):533-40
   PubMed Web of Science ®Google Scholar